-
Study aim
-
The effect of supplementation with vitamins A, D, E, C, B on disease severity and mortality in patients with COVID-19
-
Design
-
A randomized, double-blind, placebo-controlled clinical trial
-
Settings and conduct
-
Only patients are unaware of the placement in the intervention or control group. Location: The intensive care unit is located at Imam Khomeini Hospital.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria :
1- Between 20 and 60 years old
2. Both men and women
3. The definitive or clinical diagnosis of COVID-19
4. Satisfaction with the study collaboration
5.BMI: 18.5-30
6. COVID-19 treatment protocol is almost identical in both groups
7- Patients not participating in other trials
8- No liver and kidney disorders
Non-Entry Criteria:
- Patients with rare and specific viral diseases such as HIV
- Patients undergoing chemotherapy over the past month
- Any other condition that the specialist diagnoses is very specific.
-
Intervention groups
-
Patients were divided into intervention and control groups. Intervention group supplemented with vitamin D at 25,000 international units of vitamin A daily, 600,000 international units of vitamin D once daily, 300 units of vitamin E twice daily, 500 mg Vitamin C is taken 4 times a day and finally B vitamins are taken as a daily solute ampoule. The control group received no supplement or placebo.
-
Main outcome variables
-
Variables:
1- Weight, height and BMI of patients
2. Severity of pulmonary involvement according to CT scan
3. Respiratory support (Insive or Non-Invasive)
4% oxygen saturation
5- Serum levels of WBC, CRP, IL6, TNF-α, IFN-G, ESR
6. The patient's body temperature
7. The presence or absence of involvement of other organs
8- Duration of hospitalization
9. Mortality